We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza Logo

Lonza

Lonza is a healthcare manufacturing organization helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. They help their customers to deliver new and innovative medicines that treat a wide range of diseases, allowing their patients to benefit from life-saving and life-enhancing treatments.

Latest Lonza Content

Floating cells on an orange background.
Article

Challenges and Solutions in Cell Therapy Development

In this article, we explore how researchers are tackling some of the challenges preventing cell therapies from being more widely used. We also outline advances in manufacturing and regulatory approval processes that will help expand patient access to life-changing treatments.
Hepatocyte, Plateable, Induction, Drug-drug, DDI, Transporter, CYP activity, Efflux, Influx, ADME, DMPK
Product
Advertisement

Human Hepatocytes, Cryopreserved, Plateable and Interaction Qualified

Lonza's cryopreserved, plateable human hepatocytes, HUCPI, are characterized for transporter activity, enzyme activity, and enzyme gene induction potential.

Donor-matched NPCs are available. All liver-derived cells have an optimized media system for thawing, plating, and maintenance.
Assessing the Functionality of PBMCs After Cryopreservation
App Note / Case Study

Assessing the Functionality of PBMCs After Cryopreservation

As PBMCs continue to see an increase in use in the testing of new biological therapeutic compounds, ensuring purified cells retain functionality after cryopreservation is critical.
Cells.
Product News

Lonza Appoints Wolfgang Wienand as New Chief Executive Officer

Wolfgang Wienand, currently CEO of Swiss CDMO Siegfried Holding AG, will become Chief Executive Officer of Lonza in the summer of 2024. Albert M. Baehny will retire from Lonza following a transition period.
Drug Discovery: Current Approaches and Future Perspectives eBook cover
eBook

Drug Discovery: Current Approaches and Future Perspectives

Through a selection of articles, interviews and graphics, this eBook will provide readers with an overview of drug discovery, design and development, highlighting challenges and solutions, successes, various modalities and approaches.
mRNA.
Product News

Lonza and Oxford Nanopore To Collaborate on Novel Test To Accelerate Analysis of mRNA Products

Collaboration aims to commercialize a Current Good Manufacturing Practice (cGMP) validated test to enable advanced and innovative analysis for multiple critical quality attributes of mRNA products.
Scientist with an assay plate.
Product News

Jean-Marc Huët To Succeed Albert M. Baehny as Chairman of Lonza

Longstanding Chairman of Lonza, Albert Baehny will not stand for re-election. Jean-Marc Huët, currently Chairman of Heineken N.V. with strong international leadership track record to be proposed as the new Chairman of Lonza at the 2024 AGM.
A scientist in a lab.
Product News

Lonza Delivers Solid 2023 Performance With 10.9% Cer Sales Growth and 29.8% Core EBITDA Margin

Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%.
Representation of cells.
Industry Insight

Maximizing Cell Line Productivity and Efficiency

In this interview, Dr. Tabitha Bullock tells us about some of the key considerations in cell line development and how advances in technology are improving the efficiency and productivity of cell lines.
A lab worker pipetting into a plate.
Product News

Lonza’s Rapid PyroCell® Monocyte Activation Test Systems Make Rabbit-Free Pyrogen Testing Faster, Easier, and More Efficient

Lonza launched PyroCell® MAT Rapid System and PyroCell® MAT Human Serum (HS) Rapid System, two sustainable monocyte activation test (MAT) systems containing the new PeliKine Human IL-6 Rapid ELISA Kit.
Advertisement